Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
TOKYO, Dec 23, 2024 – (JCN Newswire via SeaPRwire.com) – Fujirebio Holdings, Inc., a wholly-owned subsidiary of H.U. Group Holdings, Inc., and Eisai Co., Ltd. announced today that they have entered into a memorandum of understanding for the joint research and social implementation of novel blood-based biomarkers in the field of neurodegenerative diseases.Fujirebio and Eisai have been conducting joint research on cerebrospinal fluid biomarkers related to Alzheimer’s disease (AD).The two companies have agreed to move forward with their partnership based on the shared understanding that the development andcommercialization of diagnostic methods for neurodegenerative diseases can be accelerated by integrating the long-standing respectiveexpertise of Fujirebio, which has experience in the research and development of test reagents in the neurodegenerative disease field, and Eisai, which has been engaged in the research and development of therapeutics in the field of dementia. The partners plan to explore a wide ran…